Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

Keywords

DNA methylation, Glioma, Anaplastic astrocytoma, Biology, Oligodendroglial Tumor

References

• Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarraysMartin J. Aryee, Andrew E. Jaffe, Héctor Corrada Bravo — 2014
• Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumorsPilar Mur, Manuela Mollejo, Yolanda Ruano — 2013
• The integrated landscape of driver genomic alterations in glioblastomaVeroniquè Frattini, Vladimir Trifonov, Joseph M. Chan — 2013
• Altered Telomeres in Tumors with ATRX and DAXX MutationsChristopher M. Heaphy, Roeland F. de Wilde, Yuchen Jiao — 2011
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeŞevin Turcan, Daniel Rohle, Anuj Goenka — 2012
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutaratePatrick S. Ward, Jay Patel, David R. Wise — 2010
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasChristian Hartmann, Bettina Hentschel, Wolfgang Wick — 2010
• MGMT testing—the challenges for biomarker-based glioma treatmentWolfgang Wick, Michael Weller, Martin J. van den Bent — 2014
• Mutations in CIC and FUBP1 Contribute to Human OligodendrogliomaChetan Bettegowda, Nishant Agrawal, Yuchen Jiao — 2011
• Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiaoyang Liu, Noha Gerges, Andrey Korshunov — 2012
• An Integrated Genomic Analysis of Human Glioblastoma MultiformeD. Williams Parsons, Siân Jones, Xiaosong Zhang — 2008
• Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With OutcomeJohan M. Kros, Thierry Gorlia, Mathilde C.M. Kouwenhoven — 2007
• Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous systemChristian Koelsche, Felix Sahm, David Capper — 2013
• NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.Wolfgang Wick, Christian Hartmann, Corinna Engel — 2009
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.Albert Lai, Samir Kharbanda, Whitney B. Pope — 2011
• MGMT gene silencing and benefit from temozolomide in glioblastoma.Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia — 2005
• Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaHoutan Noushmehr, Daniel J. Weisenberger, Kristin Diefes — 2010
• The Somatic Genomic Landscape of GlioblastomaCameron Brennan, Roel G.W. Verhaak, Aaron McKenna — 2013
• MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutationsShani A. Mulholland, Danita M. Pearson, Rifat Hamoudi — 2012
• Paediatric and adult glioblastoma: multiform (epi)genomic culprits emergeDominik Sturm, Sebastian Bender, David Jones — 2014

Cited by

• Machine learning classifies cancerJordi Vila Abadal, Rosa José Ferrán — 2018
• IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHODavid Reuß, Yasin Mamatjan, Daniel Schrimpf — 2015
• Klassifikation von GliomenDavid Capper, Guido Reifenberger — 2015
• Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entitiesDavid Reuß, Annekathrin Kratz, Felix Sahm — 2015
• Glioblastoma: pathology, molecular mechanisms and markersKenneth Aldape, Gelareh Zadeh, Sheila Mansouri — 2015
• Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasThe Cancer Genome Atlas Research Network — 2015
• Isocitrate dehydrogenase mutations in gliomas.Matthew S. Waitkus, Bill H. Diplas, Hai Yan — 2016
• Biomarker-driven diagnosis of diffuse gliomas.Christina Appin, Daniel J. Brat — 2015
• Oligodendroglioma: pathology, molecular mechanisms and markersPieter Wesseling, Martin J. van den Bent, Arie Perry — 2015
• Treatment of anaplastic glioma.Wolfgang Wick, Benedikt Wiestler, Michael Platten — 2015
• Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytomaFelix Sahm, David Reuß, Christian Koelsche — 2014
• Mutational landscape and clonal architecture in grade II and III gliomasHiromichi Suzuki, Kosuke Aoki, Kenichi Chiba — 2015
• ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastomaDavid Reuß, Felix Sahm, Daniel Schrimpf — 2014
• Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groupsMichael Weller, Ruthild G. Weber, Edith Willscher — 2015
• Brain tumour cells interconnect to a functional and resistant networkMatthias Osswald, Erik Jung, Felix Sahm — 2015
• Clinical impact of molecular biomarkers in gliomas.Tali Siegal — 2015
• Anaplastic glioma: current treatment and managementÉmilie Le Rhun, Sophie Taillibert, Marc C. Chamberlain — 2015
• ETV/Pea3 family transcription factor‐encoding genes are overexpressed in CIC‐mutant oligodendrogliomasVijay Padul, Sridhar Epari, Aliasgar Moiyadi — 2015
• Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials.Johan M. Kros, Karin Huizer, Aurelio Hernández‐Laín — 2015
• Gliomatosis cerebri: no evidence for a separate brain tumor entityUlrich Herrlinger, David Jones, Martin Glas — 2016

Related papers

• Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma.Ruimin Ma, Guojun Zhang, Huimin Wang — 2012
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomasKoichi Ichimura, Danita M. Pearson, Sylvia Kocialkowski — 2009
• Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation statusMakoto Ohno, Yoshitaka Narita, Yasuji Miyakita — 2012
• Radiotherapy in Supratentorial GliomasMart A. A. M. Heesters, Willemina M. Molenaar, Gwan K. Go — 2003
• Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.Satoshi Tanaka, Jiro Akimoto, Ikuo Kobayashi — 2008
• Long-term survival of glioblastoma multiforme: importance of histopathological reevaluationJürgen A. Kraus, Matthias Wenghoefer, Matthias Schmidt — 2000
• Clinical significance of the 2016 WHO classification in Japanese patients with gliomasToshihiko Iuchi, Takahiro Sugiyama, Miki Ohira — 2018
• Cytogenetic Analysis of Gemistocytic Cells in GliomasJohan M. Kros, Natanja Waarsenburg, Donal P. Hayes — 2000
• Pre-radiation Chemotherapy for Malignant Glioma in AdultsSarah Kirby, David Macdonald, Barbara Fisher — 1996
• Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.Hiroko Ohgaki, Paul Kleihues — 2005